Qiagen N.V. (QGEN) 10-Year Financial Performance & Capital Metrics

QGEN • • Industrial / General

HealthcareDiagnostics & ResearchLife Sciences Instrumentation & ToolsLaboratory Equipment & Consumables

AboutQIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.Show more

Revenue $1.98B +0.7%
EBITDA $301M -51.1%
Net Income $84M -75.5%
EPS (Diluted) 0.38 -75.8%
Gross Margin 48.9% -22.1%
EBITDA Margin 15.21% -51.4%
Operating Margin 4.94% -76.3%
Net Margin 4.23% -75.7%
ROE 2.27% -75.8%
ROIC 1.63% -75.4%
Debt/Equity 0.40 -1.4%
Interest Coverage 2.23 -71.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 25.6% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 16.7%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y3.94%

5Y5.32%

3Y-4.22%

TTM5.32%

Profit (Net Income) CAGR

10Y-3.25%

5Y-

3Y-45.37%

TTM336.2%

EPS CAGR

10Y-2.71%

5Y-

3Y-44.97%

TTM353.66%

ROCE

10Y Avg5.69%

5Y Avg8.26%

3Y Avg6.84%

Latest1.92%

Peer Comparison

Laboratory Equipment & Consumables

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
QGENQiagen N.V.	9.97B	48.38	127.32	0.66%	19.58%	11.11%	5.08%	0.40
RVTYRevvity, Inc.	13.08B	115.33	47.85	0.16%	8.47%	3.23%	4.14%	0.43
DHRDanaher Corporation	169.45B	239.89	45.35	-0.06%	14.43%	6.86%	3.13%	0.35
TMOThermo Fisher Scientific Inc.	234.69B	624.65	37.79	0.05%	15.02%	12.84%	3.1%	0.66
WATWaters Corporation	23.5B	394.59	36.84	0.07%	20.89%	27.84%	2.64%	0.93
MTDMettler-Toledo International Inc.	30.57B	1496.61	36.80	2.22%	21.2%		2.83%
AAgilent Technologies, Inc.	41.06B	144.83	31.69	6.73%	18.75%	19.33%	2.81%	0.50
TWSTTwist Bioscience Corporation	2.53B	41.27	-31.75	20.32%	-23.51%	-17.81%		0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.28B	1.34B	1.42B	1.5B	1.53B	1.87B	2.25B	2.14B	1.97B	1.98B
Revenue Growth %	-0.05%	0.04%	0.06%	0.06%	0.02%	0.23%	0.2%	-0.05%	-0.08%	0.01%
Cost of Goods Sold+	454.33M	493.34M	494.98M	500.89M	521.16M	637.63M	800.84M	756.96M	731.62M	1.01B
COGS % of Revenue	0.35%	0.37%	0.35%	0.33%	0.34%	0.34%	0.36%	0.35%	0.37%	0.51%
Gross Profit+	826.66M	844.65M	922.56M	1B	1.01B	1.23B	1.45B	1.38B	1.23B	967.35M
Gross Margin %	0.65%	0.63%	0.65%	0.67%	0.66%	0.66%	0.64%	0.65%	0.63%	0.49%
Gross Profit Growth %	-0.04%	0.02%	0.09%	0.08%	0%	0.23%	0.18%	-0.05%	-0.11%	-0.22%
Operating Expenses+	647.16M	745.83M	769.14M	734.38M	1.03B	846.28M	820.74M	853.1M	823.75M	869.64M
OpEx % of Revenue	0.51%	0.56%	0.54%	0.49%	0.68%	0.45%	0.36%	0.4%	0.42%	0.44%
Selling, General & Admin	464.84M	530.6M	575.66M	533.5M	504.17M	525.36M	584.47M	603.95M	579.17M	564.36M
SG&A % of Revenue	0.36%	0.4%	0.41%	0.36%	0.33%	0.28%	0.26%	0.28%	0.29%	0.29%
Research & Development	147.18M	176.13M	154.08M	161.85M	157.45M	149.07M	189.96M	189.86M	198.51M	193.49M
R&D % of Revenue	0.11%	0.13%	0.11%	0.11%	0.1%	0.08%	0.08%	0.09%	0.1%	0.1%
Other Operating Expenses	38.67M	39.09M	137.42M	75.68M	369.78M	171.85M	46.3M	59.3M	46.07M	111.78M
Operating Income+	179.5M	98.83M	153.42M	266.58M	-26.14M	386.43M	630.08M	531.46M	409.94M	97.71M
Operating Margin %	0.14%	0.07%	0.11%	0.18%	-0.02%	0.21%	0.28%	0.25%	0.21%	0.05%
Operating Income Growth %	0.11%	-0.45%	0.55%	0.74%	-1.1%	15.79%	0.63%	-0.16%	-0.23%	-0.76%
EBITDA+	370.97M	311.88M	369.87M	473.02M	205.32M	591.45M	845.01M	739.86M	615.27M	300.98M
EBITDA Margin %	0.29%	0.23%	0.26%	0.31%	0.13%	0.32%	0.38%	0.35%	0.31%	0.15%
EBITDA Growth %	0.87%	-0.16%	0.19%	0.28%	-0.57%	1.88%	0.43%	-0.12%	-0.17%	-0.51%
D&A (Non-Cash Add-back)	191.47M	213.06M	216.45M	206.44M	231.46M	205.01M	214.93M	208.4M	205.34M	203.27M
EBIT	173.7M	95.93M	164.06M	293.03M	-3.59M	510.79M	680.31M	570.96M	483.22M	164.99M
Net Interest Income+	-32.64M	-32.25M	-39.04M	-46.44M	-52.07M	-61.28M	-44.92M	-25.6M	25.58M	24.18M
Interest Income	4.75M	6.78M	10.64M	20.85M	22.11M	10.03M	9.55M	32.76M	78.99M	68.02M
Interest Expense	37.4M	39.02M	49.69M	67.29M	74.19M	71.32M	54.48M	58.36M	53.41M	43.84M
Other Income/Expense	-43.2M	-41.92M	-39.04M	-40.84M	-51.64M	53.04M	-4.25M	-18.86M	19.87M	23.44M
Pretax Income+	136.3M	56.91M	114.38M	225.74M	-77.78M	439.47M	625.83M	512.6M	429.81M	121.15M
Pretax Margin %	0.11%	0.04%	0.08%	0.15%	-0.05%	0.23%	0.28%	0.24%	0.22%	0.06%
Income Tax+	6.4M	-23.39M	73.98M	35.36M	-36.32M	80.28M	113.23M	89.39M	88.51M	37.56M
Effective Tax Rate %	0.95%	1.41%	0.35%	0.84%	0.53%	0.82%	0.82%	0.83%	0.79%	0.69%
Net Income+	130.15M	80.4M	40.39M	190.38M	-41.45M	359.19M	512.6M	423.21M	341.3M	83.59M
Net Margin %	0.1%	0.06%	0.03%	0.13%	-0.03%	0.19%	0.23%	0.2%	0.17%	0.04%
Net Income Growth %	0.12%	-0.38%	-0.5%	3.71%	-1.22%	9.66%	0.43%	-0.17%	-0.19%	-0.76%
Net Income (Continuing)	126.86M	80.3M	40.39M	190.38M	-41.45M	359.19M	512.6M	423.21M	341.3M	83.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	2.03M	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.56	0.35	0.17	0.82	-0.19	0.32	2.28	1.90	1.57	0.38
EPS Growth %	0.12%	-0.38%	-0.51%	3.82%	-1.23%	2.68%	6.13%	-0.17%	-0.17%	-0.76%
EPS (Basic)	0.57	0.36	0.18	0.84	-0.19	0.33	2.32	1.92	1.54	0.39
Diluted Shares Outstanding	228.37M	230.14M	233.01M	233.46M	219.97M	227.19M	225.07M	223.23M	217.49M	218.47M
Basic Shares Outstanding	224.38M	225.87M	228.07M	225.51M	219.97M	221.57M	221.14M	220.75M	217.49M	216.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	961.61M	1.04B	1.65B	2.16B	1.57B	1.62B	2.11B	2.39B	2.15B	1.96B
Cash & Short-Term Investments	423.33M	532.18M	1.04B	1.42B	753.23M	715.23M	1.07B	1.42B	1.06B	1.15B
Cash Only	292.51M	439.18M	679.62M	1.18B	623.65M	597.98M	880.52M	730.67M	668.08M	663.55M
Short-Term Investments	130.82M	93M	359.2M	234.61M	129.59M	117.25M	184.78M	687.6M	389.7M	489.44M
Accounts Receivable	325.89M	327.92M	386.1M	397.68M	484.61M	486.61M	469.66M	434.07M	515.64M	458.98M
Days Sales Outstanding	92.86	89.46	99.42	96.65	115.88	94.96	76.13	73.98	95.77	84.69
Inventory	136.59M	136.55M	155.93M	162.91M	170.7M	291.18M	327.52M	357.96M	398.38M	279.26M
Days Inventory Outstanding	109.73	101.03	114.98	118.71	119.55	166.68	149.28	172.61	198.75	100.83
Other Current Assets	36.83M	5.39M	7.48M	102.75M	116.29M	70.23M	186.48M	132.7M	130.9M	26.85M
Total Non-Current Assets+	3.23B	3.27B	3.39B	3.59B	3.67B	4.25B	4.04B	3.89B	3.97B	3.73B
Property, Plant & Equipment	442.94M	436.65M	494.32M	511.66M	455.24M	559.37M	638.18M	662.17M	765.04M	753.61M
Fixed Asset Turnover	2.89x	3.06x	2.87x	2.94x	3.35x	3.34x	3.53x	3.23x	2.57x	2.62x
Goodwill	1.88B	1.93B	2.01B	2.11B	2.14B	2.36B	2.35B	2.35B	2.48B	2.43B
Intangible Assets	636.42M	557.16M	499.32M	475.04M	632.43M	726.19M	627.44M	544.8M	526.82M	303.81M
Long-Term Investments	187.15M	55.63M	276.46M	369.69M	0	0	0	0	0	0
Other Non-Current Assets	83.82M	227.28M	68.18M	85.45M	380.65M	540.74M	348.07M	334.25M	200.04M	246.93M
Total Assets+	4.19B	4.31B	5.04B	5.75B	5.24B	5.87B	6.15B	6.29B	6.12B	5.69B
Asset Turnover	0.31x	0.31x	0.28x	0.26x	0.29x	0.32x	0.37x	0.34x	0.32x	0.35x
Asset Growth %	-0.06%	0.03%	0.17%	0.14%	-0.09%	0.12%	0.05%	0.02%	-0.03%	-0.07%
Total Current Liabilities+	268.35M	308.43M	324.79M	972.19M	951.35M	572.17M	1.52B	974.52M	1.08B	543.63M
Accounts Payable	52.31M	51.22M	59.2M	69.42M	84.77M	118.15M	101.22M	98.73M	84.16M	83.27M
Days Payables Outstanding	42.02	37.89	43.66	50.58	59.37	67.63	46.14	47.61	41.98	30.07
Short-Term Debt	922K	4.92M	10.39M	503.18M	285.24M	42.54M	847.63M	389.55M	587.97M	53.48M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	89.3M	125.98M	120.84M	257.32M	158.82M	119.31M	257.65M	192.19M	118.03M	113.21M
Current Ratio	3.58x	3.36x	5.07x	2.22x	1.65x	2.84x	1.39x	2.46x	1.99x	3.61x
Quick Ratio	3.07x	2.92x	4.59x	2.05x	1.47x	2.33x	1.17x	2.09x	1.62x	3.09x
Cash Conversion Cycle	160.57	152.59	170.74	164.78	176.07	194.01	179.28	198.98	252.53	155.45
Total Non-Current Liabilities+	1.36B	1.39B	2.17B	2.14B	1.75B	2.5B	1.53B	1.85B	1.23B	1.58B
Long-Term Debt	1.06B	1.07B	1.76B	1.67B	1.42B	1.88B	1.09B	1.47B	921.82M	1.34B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	75.73M	40.62M	76.73M	63.41M	23.44M	39.22M	37.59M	0	0	0
Other Non-Current Liabilities	224.06M	279.06M	337.74M	406.67M	303.13M	580.18M	401.2M	374.7M	306.31M	240.59M
Total Liabilities	1.63B	1.7B	2.5B	3.11B	2.7B	3.07B	3.05B	2.82B	2.31B	2.12B
Total Debt+	1.06B	1.08B	1.77B	2.17B	1.73B	1.95B	1.96B	1.88B	1.53B	1.42B
Net Debt	768M	638.73M	1.09B	989.82M	1.1B	1.35B	1.08B	1.15B	863.98M	752.33M
Debt / Equity	0.41x	0.41x	0.70x	0.83x	0.68x	0.70x	0.63x	0.54x	0.40x	0.40x
Debt / EBITDA	2.86x	3.46x	4.78x	4.60x	8.40x	3.29x	2.32x	2.55x	2.49x	4.70x
Net Debt / EBITDA	2.07x	2.05x	2.94x	2.09x	5.36x	2.28x	1.28x	1.56x	1.40x	2.50x
Interest Coverage	4.80x	2.53x	3.09x	3.96x	-0.35x	5.42x	11.57x	9.11x	7.68x	2.23x
Total Equity+	2.56B	2.61B	2.54B	2.63B	2.54B	2.8B	3.1B	3.47B	3.81B	3.57B
Equity Growth %	-0.01%	0.02%	-0.03%	0.04%	-0.04%	0.1%	0.11%	0.12%	0.1%	-0.06%
Book Value per Share	11.22	11.33	10.91	11.29	11.53	12.32	13.76	15.53	17.51	16.33
Total Shareholders' Equity	2.56B	2.61B	2.54B	2.63B	2.54B	2.8B	3.1B	3.47B	3.81B	3.57B
Common Stock	2.81M	2.81M	2.7M	2.7M	2.7M	2.7M	2.7M	2.7M	2.7M	2.6M
Retained Earnings	1.23B	1.26B	1.25B	1.38B	1.18B	1.32B	1.79B	2.16B	2.46B	2.45B
Treasury Stock	-152.41M	-120.01M	-118.99M	-178.9M	-111.97M	-118.3M	-189.73M	-160.19M	-133.02M	-74.92M
Accumulated OCI	-259.16M	-333.84M	-220.76M	-310.64M	-309.62M	-243.82M	-326.67M	-404.09M	-433.83M	-474.54M
Minority Interest	2.03M	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	317.5M	341.6M	286.78M	359.5M	330.84M	492.27M	639M	715.26M	459.45M	673.55M
Operating CF Margin %	0.25%	0.26%	0.2%	0.24%	0.22%	0.26%	0.28%	0.33%	0.23%	0.34%
Operating CF Growth %	0.1%	0.08%	-0.16%	0.25%	-0.08%	0.49%	0.3%	0.12%	-0.36%	0.47%
Net Income	126.86M	80.3M	40.39M	190.38M	-41.45M	73.64M	512.6M	423.21M	341.3M	83.59M
Depreciation & Amortization	191.47M	213.06M	216.45M	206.44M	231.46M	209.97M	214.93M	208.4M	205.34M	203.27M
Stock-Based Compensation	27.57M	28.29M	34.44M	40.11M	65.89M	40.94M	38.39M	49.51M	47.1M	43.63M
Deferred Taxes	-37.19M	-65.97M	39.55M	-23.27M	-55.36M	-14.26M	-5.29M	-9.6M	10.73M	-23.04M
Other Non-Cash Items	89.91M	75.64M	23.18M	41M	174.63M	165.18M	8.38M	75.63M	41.94M	230.65M
Working Capital Changes	-81.11M	10.29M	-67.23M	-95.16M	-44.32M	16.8M	-130.01M	-31.88M	-186.96M	135.45M
Change in Receivables	-24.76M	-12.24M	-34.16M	-41.81M	-39.58M	-14.71M	-7.4M	15.45M	-55.12M	12.22M
Change in Inventory	-33.19M	-20.35M	-21.63M	-36.92M	-30.03M	-107.57M	-81.8M	-61.95M	-44.79M	87.75M
Change in Payables	7.73M	-1.47M	4.32M	6.99M	9.25M	8.44M	-5.97M	-1.76M	-22.42M	1.45M
Cash from Investing+	-146.2M	-179.06M	-464.26M	-211.36M	-222.28M	-453.29M	-202.43M	-726.76M	-87.66M	-249.23M
Capital Expenditures	-117.48M	-93.92M	-124.41M	-150.76M	-274.88M	-304.24M	-206.53M	-149.34M	-162.8M	-167.17M
CapEx % of Revenue	0.09%	0.07%	0.09%	0.1%	0.18%	0.16%	0.09%	0.07%	0.08%	0.08%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-5.88M	-8.74M	-22.98M	-2.13M	22.7M	-66.57M	61.47M	-9.77M	-66.55M	21.35M
Cash from Financing+	-258.61M	-10.6M	387.19M	360.41M	-639.08M	-74.32M	-150.37M	-125.8M	-433.83M	-422.9M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.84M	-8.81M	-30.76M	-28.48M	-61.28M	39.07M	-16.95M	-17.37M	2.77M	-23.47M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	200.02M	247.68M	162.37M	208.73M	55.96M	188.03M	432.47M	565.93M	296.65M	506.38M
FCF Margin %	0.16%	0.19%	0.11%	0.14%	0.04%	0.1%	0.19%	0.26%	0.15%	0.26%
FCF Growth %	0.05%	0.24%	-0.34%	0.29%	-0.73%	2.36%	1.3%	0.31%	-0.48%	0.71%
FCF per Share	0.88	1.08	0.70	0.89	0.25	0.83	1.92	2.54	1.36	2.32
FCF Conversion (FCF/Net Income)	2.44x	4.25x	7.10x	1.89x	-7.98x	1.37x	1.25x	1.69x	1.35x	8.06x
Interest Paid	20.8M	18.23M	20.25M	25.9M	29.72M	25.35M	21.59M	23.21M	20.35M	24.18M
Taxes Paid	34.44M	22.67M	40.5M	29.32M	41.47M	42.57M	102.08M	120.48M	82.41M	15.68M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.05%	3.11%	1.57%	7.36%	-1.6%	13.47%	17.39%	12.9%	9.38%	2.27%
Return on Invested Capital (ROIC)	3.96%	2.25%	3.35%	5.51%	-0.54%	7.45%	11.35%	9.06%	6.62%	1.63%
Gross Margin	64.53%	63.13%	65.08%	66.65%	65.86%	65.91%	64.43%	64.65%	62.77%	48.9%
Net Margin	10.16%	6.01%	2.85%	12.68%	-2.72%	19.2%	22.77%	19.76%	17.37%	4.23%
Debt / Equity	0.41x	0.41x	0.70x	0.83x	0.68x	0.70x	0.63x	0.54x	0.40x	0.40x
Interest Coverage	4.80x	2.53x	3.09x	3.96x	-0.35x	5.42x	11.57x	9.11x	7.68x	2.23x
FCF Conversion	2.44x	4.25x	7.10x	1.89x	-7.98x	1.37x	1.25x	1.69x	1.35x	8.06x
Revenue Growth	-4.74%	4.45%	5.95%	5.95%	1.64%	22.53%	20.39%	-4.89%	-8.23%	0.66%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Diagnostic Solutions	-	-	-	-	-	460.76M	638.76M	660.88M	697.63M	748.89M
Diagnostic Solutions Growth	-	-	-	-	-	-	38.63%	3.46%	5.56%	7.35%
Sample Technologies	-	-	-	-	-	803.87M	850.64M	796.93M	662.99M	642.03M
Sample Technologies Growth	-	-	-	-	-	-	5.82%	-6.31%	-16.81%	-3.16%
PCR / Nucleic Acid Amplification	-	-	-	-	-	363.55M	433.97M	390.8M	300.2M	300.47M
PCR / Nucleic Acid Amplification Growth	-	-	-	-	-	-	19.37%	-9.95%	-23.18%	0.09%
Genomics / NGS	-	-	-	-	-	165.57M	245.07M	224.8M	238.91M	233.61M
Genomics / NGS Growth	-	-	-	-	-	-	48.01%	-8.27%	6.28%	-2.22%
Product and Service, Other	-	-	-	-	-	76.6M	83.22M	68.11M	65.58M	53.22M
Product and Service, Other Growth	-	-	-	-	-	-	8.65%	-18.17%	-3.71%	-18.84%
Consumables and Related	-	-	-	2.63B	2.04B	-	-	-	-	-
Consumables and Related Growth	-	-	-	-	-22.37%	-	-	-	-	-
Instruments	-	-	-	372.78M	445.56M	-	-	-	-	-
Instruments Growth	-	-	-	-	19.53%	-	-	-	-	-
Consumables and Related Revenues	1.11B	1.17B	1.24B	-	-	-	-	-	-	-
Consumables and Related Revenues Growth	-	4.63%	6.57%	-	-	-	-	-	-	-
Instrumentation	166.41M	171.86M	174.82M	-	-	-	-	-	-	-
Instrumentation Growth	-	3.28%	1.72%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Americas	605.11M	627.47M	653.38M	693.02M	721.99M	825.46M	1.01B	997.75M	1.02B	1.03B
Total Americas Growth	-	3.70%	4.13%	6.07%	4.18%	14.33%	22.04%	-0.96%	2.24%	1.13%
EMEA	409.95M	428.06M	462.98M	490.3M	487.48M	682.29M	814.42M	733.47M	624.57M	648.49M
EMEA Growth	-	4.42%	8.16%	5.90%	-0.58%	39.96%	19.37%	-9.94%	-14.85%	3.83%
Asia Pacific and World	265.92M	282.46M	301.17M	318.53M	316.96M	362.6M	429.86M	410.29M	320.68M	298.15M
Asia Pacific and World Growth	-	6.22%	6.62%	5.76%	-0.49%	14.40%	18.55%	-4.55%	-21.84%	-7.03%

Frequently Asked Questions

Valuation & Price

Qiagen N.V. (QGEN) has a price-to-earnings (P/E) ratio of 127.3x. This suggests investors expect higher future growth.

Growth & Financials

Qiagen N.V. (QGEN) reported $2.07B in revenue for fiscal year 2024. This represents a 77% increase from $1.17B in 2011.

Qiagen N.V. (QGEN) grew revenue by 0.7% over the past year. Growth has been modest.

Yes, Qiagen N.V. (QGEN) is profitable, generating $405.4M in net income for fiscal year 2024 (4.2% net margin).

Dividend & Returns

Qiagen N.V. (QGEN) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.

Qiagen N.V. (QGEN) generated $477.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...